secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000898432-22-000631
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iRadimed Q3 revenue up 23% to $13.4M; GAAP EPS $0.27; guides Q4 rev $14.1-14.8M
-------------------------------------------------------------------------------

- Q3 revenue $13.4M (+23% YoY), operating income $4.1M (+32%), GAAP EPS $0.27 (+35%).
- Non-GAAP net income $3.7M (excl. $0.3M stock comp); nine-month non-GAAP EPS $0.78 vs $0.50.
- Gross margin improved to 78.6% from 77.1%; operating cash flow $3.9M in Q3.
- Q4 guidance: revenue $14.1-14.8M, GAAP EPS $0.23-0.28, non-GAAP EPS $0.25-0.30.
- CEO cites strong bookings and backlog; purchased 27 acres in Orlando for future HQ, tripling space.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000089843222000631/0000898432-22-000631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000089843222000631/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0000898432-22-000631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer